CN112522364A - Uric acid kit for quickly and simply eliminating interference of calcium dobesilate and etamsylate medicines in serum - Google Patents
Uric acid kit for quickly and simply eliminating interference of calcium dobesilate and etamsylate medicines in serum Download PDFInfo
- Publication number
- CN112522364A CN112522364A CN202011578743.9A CN202011578743A CN112522364A CN 112522364 A CN112522364 A CN 112522364A CN 202011578743 A CN202011578743 A CN 202011578743A CN 112522364 A CN112522364 A CN 112522364A
- Authority
- CN
- China
- Prior art keywords
- reagent
- trinder
- serum
- uric acid
- calcium dobesilate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QGNBTYAQAPLTMX-UHFFFAOYSA-L calcium dobesilate Chemical compound [Ca+2].OC1=CC=C(O)C(S([O-])(=O)=O)=C1.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 QGNBTYAQAPLTMX-UHFFFAOYSA-L 0.000 title claims abstract description 47
- 229960005438 calcium dobesilate Drugs 0.000 title claims abstract description 47
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 46
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 229940116269 uric acid Drugs 0.000 title claims abstract description 46
- HBGOLJKPSFNJSD-UHFFFAOYSA-N Etamsylate Chemical compound CC[NH2+]CC.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 HBGOLJKPSFNJSD-UHFFFAOYSA-N 0.000 title claims abstract description 45
- 229960004817 etamsylate Drugs 0.000 title claims abstract description 45
- 210000002966 serum Anatomy 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 229940079593 drug Drugs 0.000 title claims abstract description 21
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 94
- 102000003992 Peroxidases Human genes 0.000 claims abstract description 18
- 108040007629 peroxidase activity proteins Proteins 0.000 claims abstract description 18
- 239000007853 buffer solution Substances 0.000 claims abstract description 17
- 239000003755 preservative agent Substances 0.000 claims abstract description 17
- 230000002335 preservative effect Effects 0.000 claims abstract description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 15
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 14
- 102000004316 Oxidoreductases Human genes 0.000 claims abstract description 13
- 108090000854 Oxidoreductases Proteins 0.000 claims abstract description 13
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 12
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 12
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 12
- 108010071390 Serum Albumin Proteins 0.000 claims abstract description 7
- 102000007562 Serum Albumin Human genes 0.000 claims abstract description 7
- 239000000872 buffer Substances 0.000 claims abstract description 5
- 108010092464 Urate Oxidase Proteins 0.000 claims description 23
- GNTDGMZSJNCJKK-UHFFFAOYSA-N divanadium pentaoxide Chemical compound O=[V](=O)O[V](=O)=O GNTDGMZSJNCJKK-UHFFFAOYSA-N 0.000 claims description 22
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 claims description 17
- 239000000376 reactant Substances 0.000 claims description 14
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 239000007800 oxidant agent Substances 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 230000001590 oxidative effect Effects 0.000 claims description 9
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 claims description 8
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 8
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 6
- 239000007995 HEPES buffer Substances 0.000 claims description 6
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 229910021538 borax Inorganic materials 0.000 claims description 6
- 239000004328 sodium tetraborate Substances 0.000 claims description 6
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 6
- IRQRBVOQGUPTLG-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 IRQRBVOQGUPTLG-UHFFFAOYSA-M 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 claims description 5
- -1 TRTS Chemical compound 0.000 claims description 5
- 239000007983 Tris buffer Substances 0.000 claims description 5
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 claims description 4
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 claims description 4
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 claims description 4
- RZQXOGQSPBYUKH-UHFFFAOYSA-N 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCC(CO)(CO)NCC(O)CS(O)(=O)=O RZQXOGQSPBYUKH-UHFFFAOYSA-N 0.000 claims description 4
- XCBLFURAFHFFJF-UHFFFAOYSA-N 3-[bis(2-hydroxyethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCCN(CCO)CC(O)CS(O)(=O)=O XCBLFURAFHFFJF-UHFFFAOYSA-N 0.000 claims description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 4
- 108700016232 Arg(2)-Sar(4)- dermorphin (1-4) Proteins 0.000 claims description 4
- 108010008488 Glycylglycine Proteins 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 239000007993 MOPS buffer Substances 0.000 claims description 4
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 claims description 4
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 claims description 4
- 239000007990 PIPES buffer Substances 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 claims description 4
- 239000007994 TES buffer Substances 0.000 claims description 4
- 239000007997 Tricine buffer Substances 0.000 claims description 4
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 claims description 4
- 239000007998 bicine buffer Substances 0.000 claims description 4
- ZHXZNKNQUHUIGN-UHFFFAOYSA-N chloro hypochlorite;vanadium Chemical compound [V].ClOCl ZHXZNKNQUHUIGN-UHFFFAOYSA-N 0.000 claims description 4
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 4
- YDBHVMTTYXWHLI-UHFFFAOYSA-N 2,4,6-tribromo-3-hydroxybenzoic acid Chemical compound OC(=O)C1=C(Br)C=C(Br)C(O)=C1Br YDBHVMTTYXWHLI-UHFFFAOYSA-N 0.000 claims description 3
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 claims description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 3
- 229960005091 chloramphenicol Drugs 0.000 claims description 3
- DPXDJGUFSPAFJZ-UHFFFAOYSA-L disodium;4-[3-methyl-n-(4-sulfonatobutyl)anilino]butane-1-sulfonate Chemical compound [Na+].[Na+].CC1=CC=CC(N(CCCCS([O-])(=O)=O)CCCCS([O-])(=O)=O)=C1 DPXDJGUFSPAFJZ-UHFFFAOYSA-L 0.000 claims description 3
- 229940043257 glycylglycine Drugs 0.000 claims description 3
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 claims description 3
- SVLRFMQGKVFRTB-UHFFFAOYSA-M sodium;3-(3,5-dimethoxyanilino)-2-hydroxypropane-1-sulfonate Chemical compound [Na+].COC1=CC(NCC(O)CS([O-])(=O)=O)=CC(OC)=C1 SVLRFMQGKVFRTB-UHFFFAOYSA-M 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000002211 L-ascorbic acid Substances 0.000 claims description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- NMWCVZCSJHJYFW-UHFFFAOYSA-M sodium;3,5-dichloro-2-hydroxybenzenesulfonate Chemical compound [Na+].OC1=C(Cl)C=C(Cl)C=C1S([O-])(=O)=O NMWCVZCSJHJYFW-UHFFFAOYSA-M 0.000 claims 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 abstract description 16
- 238000005259 measurement Methods 0.000 abstract description 16
- 229940109239 creatinine Drugs 0.000 abstract description 8
- 238000001514 detection method Methods 0.000 abstract description 6
- 102000016938 Catalase Human genes 0.000 abstract 1
- 108010053835 Catalase Proteins 0.000 abstract 1
- 108010077078 Creatinase Proteins 0.000 abstract 1
- 108010029541 Laccase Proteins 0.000 abstract 1
- 108010060059 Sarcosine Oxidase Proteins 0.000 abstract 1
- 102000008118 Sarcosine oxidase Human genes 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 229910052751 metal Inorganic materials 0.000 description 8
- 239000002184 metal Substances 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 238000003908 quality control method Methods 0.000 description 6
- JBIQAPKSNFTACH-UHFFFAOYSA-K vanadium oxytrichloride Chemical compound Cl[V](Cl)(Cl)=O JBIQAPKSNFTACH-UHFFFAOYSA-K 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000033116 oxidation-reduction process Effects 0.000 description 4
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 4
- 201000005569 Gout Diseases 0.000 description 3
- 239000012482 calibration solution Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- ALTWGIIQPLQAAM-UHFFFAOYSA-N metavanadate Chemical compound [O-][V](=O)=O ALTWGIIQPLQAAM-UHFFFAOYSA-N 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- LBSANEJBGMCTBH-UHFFFAOYSA-N manganate Chemical compound [O-][Mn]([O-])(=O)=O LBSANEJBGMCTBH-UHFFFAOYSA-N 0.000 description 2
- 230000004144 purine metabolism Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 125000005287 vanadyl group Chemical group 0.000 description 2
- BOUSMGITTRHFHS-UHFFFAOYSA-N 3,4-dichloro-2-hydroxybenzenesulfonic acid Chemical compound OC1=C(Cl)C(Cl)=CC=C1S(O)(=O)=O BOUSMGITTRHFHS-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 208000031868 Calculus ureteric Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 101710132588 Peroxidase 9 Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101100006352 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CHS5 gene Proteins 0.000 description 1
- 208000000014 Ureteral Calculi Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 208000010501 heavy metal poisoning Diseases 0.000 description 1
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- HDARHUHTZKLJET-UHFFFAOYSA-M sodium;3-(n-ethyl-3,5-dimethoxyanilino)-2-hydroxypropane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC(OC)=CC(OC)=C1 HDARHUHTZKLJET-UHFFFAOYSA-M 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/62—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving uric acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2326/00—Chromogens for determinations of oxidoreductase enzymes
- C12Q2326/90—Developer
- C12Q2326/96—4-Amino-antipyrine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90219—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
- G01N2333/90222—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3) in general
- G01N2333/90225—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3) in general with a definite EC number (1.10.3.-)
- G01N2333/90235—Ascorbate oxidase (1.10.3.3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
- G01N2333/90688—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on other nitrogen compounds as donors (1.7)
- G01N2333/90694—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3), e.g. uricase (1.7.3.3)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention relates to a uric acid kit for quickly and simply eliminating interference of calcium dobesilate and etamsylate medicines in serum, which has the technical scheme that: the reagent comprises a reagent R1 and a reagent R2, wherein the reagent R1 comprises buffer solution, creatinase, sarcosine oxidase, ascorbic acid oxidase, peroxidase or catalase, serum albumin, a nonionic surfactant, a preservative, Trinder's reagent A, laccase or metallate; the reagent R2 contained buffer, serum albumin, creatinine, preservative, and Trinder's reagent B. The invention overcomes the defect that the creatinine measurement is inaccurate due to negative deviation caused by calcium dobesilate and etamsylate contained in serum samples when creatinine is measured in clinical examination of various hospitals at present, and is suitable for serum creatinine detection of a full-automatic biochemical analyzer.
Description
The present case is the divisional application, specifically is application number: 2020108215098, the name is: a uric acid kit capable of eliminating interference of calcium dobesilate and etamsylate medicines in serum and a preparation method thereof are disclosed, and the application date is as follows: 2020.08.15.
Technical Field
The invention belongs to the technical field of medical examination, and relates to a uric acid kit for quickly and simply eliminating interference of calcium dobesilate and etamsylate medicines in serum.
Background
Uric Acid (UA) is the end product of purine metabolism in vivo, and is weakly acidic. Uric acid can be obtained from the body or from the catabolism of purines in food. In vivo, uric acid is mainly produced in the liver, a small part of which is excreted through the liver along with bile, and the majority of the rest is excreted from the kidney. Uric acid has low solubility and is therefore likely to crystallize at a high in vivo concentration. Uric acid is considered to be closely related to the occurrence and development of gout, cardiovascular and cerebrovascular diseases, metabolic syndrome, ureteral calculus, kidney diseases, and the like. In recent years, the number of people suffering from hyperuricemia and gout has been on the rise with the improvement of living standard and the change of inclusion structure of people, especially the increase of food intake rich in protein and purine. Therefore, the clinical detection of the serum uric acid concentration has very important reference value and significance, and the detection principle is as follows:
the existing commercial detection kit is double reagents, the uricase-peroxidase coupling method based on Trinder reaction has the advantages of sensitivity, suitability for automatic biochemical analyzers and the like, a reagent R1 contains peroxidase and Trinder's A reagent, after R2 is added, R2 contains uricase and Trinder's reagent B, the uricase hydrolyzes uric acid into allantoin and H2O2, and H2O2 and the peroxidase in R1 and the Trinder's A reagent are jointly existed for color generation and determination. The reaction process utilizes the specificity of enzyme, but generates H2O2Is a strong oxidant, and is easily consumed by reducing drugs in serum to generate negative interference.
Uric acid is the final metabolite of purine when purine metabolism is abnormal or renal pairingUric acid excretion disorder can cause the increase or decrease of uric acid concentration in blood; gout, renal dysfunction, malignant tumor, heavy metal poisoning such as cadmium and lead can cause the increase of blood uric acid concentration, and the blood uric acid content can be reduced due to the taking of medicines such as salicylic acid and purinol and the increase of renal excretion due to severe liver diseases. Calcium dobesilate is used as a common medicine for protecting and treating capillaries, etamsylate is used as a common medicine for stopping bleeding, the medicines are strong reducing agents, and when a patient taking the medicines measures the content of uric acid in blood plasma, the reducing medicines and uricase decompose H generated by uric acid to generate2O2Direct reaction, consuming H2O2The negative deviation of the uric acid level can be serious, and the misjudgment of the doctor during diagnosis and treatment can be caused.
Disclosure of Invention
The invention discloses a uric acid kit for quickly and simply eliminating interference of calcium dobesilate and etamsylate medicines in serum, wherein one or more of oxidation type metal acid salt with high oxidation-reduction potential, vanadium pentoxide or vanadium oxytrichloride is/are added into a reagent R1, and calcium dobesilate and etamsylate are oxidized by utilizing the oxidation characteristic of the metal acid salt, vanadium pentoxide or vanadium oxytrichloride, so that H2O2 generated by decomposition of uric acid by uricase after the reagent R2 is added is prevented from being consumed, the operation is simple, and accurate uric acid measurement value is quickly obtained.
The invention also discloses a uric acid kit for quickly and simply eliminating interference of calcium dobesilate and etamsylate medicines in serum, which comprises a reagent R1 and a reagent R2, wherein the reagent R1 comprises buffer solution, peroxidase, ascorbic acid oxidase, preservative, Trinder's reactant A and metal acid salt; the reagent R2 contains buffer, serum albumin, uricase, preservative, and Trinder's reagent B. The proper metal acid salt is selected as the oxidant to eliminate the negative deviation caused by the interference of calcium dobesilate and etamsylate in serum during the uric acid determination, simultaneously the stability of each component in the reagent R1 and the reagent R2 is not influenced, the calcium dobesilate and the etamsylate in the serum can be oxidized before the uricase (the reagent R2) is added, and the consumption of H generated during the uric acid determination is avoided2O2So that the uric acid measurement value is accurate.
Preferably, the metalate comprises one or more of oxidation state nickelate, ferrite, cobaltate, chromate, manganate and vanadate, the vanadate is one or more of metavanadate, poly-vanadate, vanadium pentoxide or vanadium oxytrichloride, and the high oxidation-reduction potential metalate comprises sodium, potassium and ammonium salts containing the metal acid. In multiple experiments, it is found that the oxidation states nickelate, cobaltate, chromate, manganate, vanadate, metavanadate, polyvanadate, vanadic anhydride or vanadyl trichloride with high oxidation-reduction potential can be selected as oxidants to eliminate negative deviation caused by interference of calcium dobesilate and etamsylate in serum during uric acid determination by adopting 23, 24, 25, 26, 27 and 28 bits of metal element acid salts in the periodic table of elements, and the stability of each component in the reagent R1 and the reagent R2 is not influenced.
Preferably, the Trinder's reactant A is 4-Aminoantipyrine (4-Aminoantipyrine, 4-AAP for short). In a series of experiments, the invention discovers that 4-AAP can coexist with the metal acid salt or vanadium pentoxide and vanadium oxychloride as well as other components in the reagent R1 only by adding the reagent R1, and Trinder's reacts with another reagent phenol compound and uricase to coexist in the reagent R2, so that the uric acid kit can eliminate the interference of calcium dobesilate and phenolsulfoethylamine, can keep the stability of the kit for more than one year at the temperature of 2-8 ℃, and can effectively reduce the interference of ascorbic acid in blood samples on uric acid determination when the amount of the ascorbic acid oxidase is in the range.
Preferably, in the reagent R1, the concentration of a buffer solution is 5-200 mM, and the pH value is 6.5-9.5;
the content of the peroxidase is 1.0-10 ku/L;
1.0-10 ku/L ascorbic acid oxidase;
trinder's reagent A0.3-5 mM/L;
when the weight ratio of the preservative is 0.01-0.5%, a metalate oxidant or a vanadium pentoxide or a vanadium oxychloride oxidant with the content of 0.1-10 mM is adopted.
Preferably, the buffer solution of the reagent R1 is one or more of BES, BICINE, DIPSO, EPPS, PIPES, HEPES, MOPS, TAPS, TAPSO, TES, Tricine, Tris, glycylglycine and phosphate; the buffer solution of the reagent R2 is one or more of BES, BICINE, DIPSO, EPPS, PIPES, HEPES, MOPS, TAPS, TAPSO, TES, TRICINE, TRIS, diglycine and phosphate.
Preferably, the reagent R1 and the reagent R2 further contain a nonionic surfactant, the weight ratio of the nonionic surfactant is 0.01-0.3%, and the nonionic surfactant is specifically one or two of BRIJ, EMULGEN, TRITON and TWEEN.
Preferably, the preservative is one or two of Proclin, gentamicin sulfate, PARABEN, chloramphenicol, sodium azide and borax. The antiseptic can inhibit the action of biological enzyme in the reagent, so that the reagent can keep stable efficacy in a certain time, such as borax, sodium azide and the like.
Preferably, in the reagent R2, the concentration of a buffer solution is 10-200 mM, and the pH value is 6.5-9.0; the uricase content is 5-20 ku/liter; the Trinder's reagent B content is 0.1-20 mM.
Preferably, the Trinder's reagent B in the reagent R2 is one or more of TOOS, DHBS, DAOS, HDAOS, TBHBA, TOPS, TODB and 4-chlorophenol.
A preparation method of a uric acid kit for quickly and simply eliminating interference of calcium dobesilate and etamsylate medicines in serum comprises the following steps: preparation of reagent R1:
weighing buffer solution → adding preservative → stirring and dissolving → adjusting pH to 8.0 with sodium hydroxide or hydrochloric acid → adding metalate → stirring and dissolving → adjusting pH to 8.0 → adding Trinder's reactant A and nonionic surfactant, mixing uniformly → 2-8 ℃ overnight → adding ascorbic acid oxidase and peroxidase → stirring and dissolving → 2-8 ℃ overnight → detecting, and subpackaging;
preparation of reagent R2:
weighing buffer solution → adding preservative → stirring and dissolving → adjusting pH to 8.0 → adding Trinder's reactant B and surfactant → mixing evenly → overnight at 2-8 deg.C → adding serum albumin, uricase → mixing evenly → overnight at 2-8 deg.C → detecting and subpackaging.
The uric acid kit consists of a reagent R1 and a reagent R2, wherein the reagent R1 is firstly mixed with a specimen, and if the specimen contains calcium dobesilate or etamsylate as a therapeutic drug, the oxidized metal acid salt or vanadium pentoxide or vanadium oxytrichloride in the reagent R1 can be oxidized firstly, so that H generated by the reaction of uricase added into the reagent R2 is avoided2O2Consumed by the above-mentioned medicine, at the same time the reagent R2 contains Trinder's reactant B, i.e. phenol compound and H produced by reaction of 4-AAP in reagent R1 and uricase2O2Color is developed, the absorbance is measured, and the content is calculated.
The invention has the beneficial effects that:
the uric acid kit capable of eliminating interference of calcium dobesilate and etamsylate in serum has the advantages of good stability, simplicity in operation and rapidness in detection reaction, particularly, peroxidase and uricase are respectively prepared in a reagent R1 and a reagent R2, and the kit is different from the existing kit components in the market, can prolong the stability of the kit within a period of time, continuously eliminates negative interference of calcium dobesilate and etamsylate, avoids misjudgment of doctors in clinical diagnosis, can accurately use medicines and treat, and is suitable for a full-automatic biochemical analyzer.
The preparation method of the uric acid kit capable of eliminating interference of calcium dobesilate and etamsylate in serum has the advantages of good kit stability, simplicity and rapidness in operation, elimination of negative interference of calcium dobesilate and etamsylate, high accuracy and suitability for a full-automatic biochemical analyzer.
Detailed Description
The uric acid kit capable of eliminating interference of calcium dobesilate and etamsylate in serum of the invention is further described by combining specific embodiments as follows:
the interference of calcium dobesilate and etamsylate is determined by a uricase method kit which is currently sold and approved by the national drug administration of China, and the results are shown in the table I:
the reagent composition is as follows in the specification:
[ major Components]From the reagent R1Reagent R2And a calibrator.
Reagent R1: dichlorohydroxybenzenesulfonic acid (DHBS), phosphate buffer;
reagent R2: uricase, peroxidase (in cross-substrate peroxidase in the component of R1), 4-aminoantipyrine.
Calibration products: the creatinine-containing aqueous solution with the concentration shown in the label can be traced to the Randox CAL3 calibrator.
[ measurement method ]
(1) The double reagents are not required to be prepared and are directly used.
(2) The test conditions are as follows: sample (S): 3 μ l reagent 1 (R1): 240 μ l reagent 2 (R2): temperature of 60. mu.l: 37 deg.C
The determination type is as follows: dominant wavelength of endpoint method: sub-wavelength of 505 nm: 660nm reaction direction: rise up
The method comprises the following steps: the standard or sample is mixed with R1, the reagent R2 is added after 5 minutes at 37 ℃, and then the reaction absorbance 5 minutes after the reagent R2 is added is measured.
Sample preparation: 3 μ l
R1:240μl R2:60μl
(3) And (3) calibration procedure: calibration is performed using a calibrator, which should be performed each time a reagent batch is changed. After calibration, each laboratory was verified with quality controls. If the quality control result is not in the acceptable range value, recalibration is needed.
(4) Quality control procedure: selecting proper quality control material for quality control. And establishing respective quality control frequency and acceptable range value by each laboratory. When the measurement result is out of the acceptable range, it is necessary to take corresponding measures.
(5) Computing
Measurement instruments and parameters:
unit: mu mol/L, normal value 90-420 mu mol/L
The measuring instrument: hitachi 7180
Measurement parameters are as follows: r1: r2: (sample size) 240:60: 3. mu.l
Primary/secondary wavelength: 505/660nm
2POINT END,INC.
Table 1 interference results determined by the existing two-reagent creatinine enzymatic kit: (unit: mu mol/L)
And (4) conclusion: the measurement result shows that calcium dobesilate and etamsylate both cause negative deviation on the uric acid measurement result.
Specifically, the effect of the uric acid kit capable of eliminating interference of calcium dobesilate and etamsylate in serum is described in combination with examples 1 to 4:
table 2 reagent components for examples 1-4:
the creatinine reagents according to the present invention are described in detail as follows:
example 1:
reagent R1 component:
tris buffer 50mM pH8.0;
peroxidase 9 ku/L;
ascorbic acid oxidase 6 ku/L;
vanadium pentoxide is 1 mM;
4-AAP 3mM;
TRITON X-100 0.2%;
borax 1%
Reagent R2 component:
tris buffer 50mM pH8.0
Uricase 9ku/L
Bovine serum albumin 0.1%
TOOS 10mM
1.0 percent of borax
TRITON 0.1%。
Example 2:
reagent R1 component:
HEPES buffer 50mM pH8.0
Peroxidase 7.2ku/L
Ascorbic acid oxidase 6.4ku/L
Sodium ferrate 1mM
4-AAP 3mM
TRITON X-100 0.2%
0.1% of gentamicin sulfate;
reagent R2 component:
HEPES buffer 50mM pH8.0
Uricase 11.2ku/L
Bovine serum albumin 0.1%
TOOS 10mM
0.1 percent of gentamicin sulfate
TRITON 0.1%。
Example 3:
reagent R1 component:
phosphate buffer 50mM pH8.0
Peroxidase 4.6ku/L
Ascorbic acid oxidase 10ku/L
Sodium metavanadate 2mM
4-AAP 3mM
TRITON X-100 0.2%
0.1% of sodium azide;
reagent R2 component:
phosphate buffer 50mM pH8.0
Uricase 20ku/L
Bovine serum albumin 0.1%
TOOS 10mM
Sodium azide 0.1%
TRITON X-100 0.1%。
Example 4:
reagent R1 component:
EPPS buffer 50mM pH8.0
Peroxidase 6.5ku/L
Ascorbic acid oxidase 5.5ku/L
Vanadium oxytrichloride 2mM
4-AAP 3mM
Brij 0.1%
Proclin 300 0.1%;
Reagent R2 component:
EPPS buffer 50mM pH8.0
Uricase 16.8ku/L
Bovine serum albumin 0.1%
TOPS 10mM
Brij 0.1%
Proclin 300 0.1%。
The preparation process of examples 1-4 comprises the following steps:
preparation of reagent R1:
weighing buffer solution → adding preservative → stirring and dissolving → adjusting pH to 8.0 with sodium hydroxide or hydrochloric acid → adding metalate → stirring and dissolving → adjusting pH to 8.0 → adding Trinder's reactant A and nonionic surfactant, mixing uniformly → 2-8 ℃ overnight → adding ascorbic acid oxidase and peroxidase → stirring and dissolving → 2-8 ℃ overnight → detecting, and subpackaging;
preparation of reagent R2:
weighing buffer solution → adding preservative → stirring and dissolving → adjusting pH to 8.0 → adding Trinder's reactant B and surfactant → mixing evenly → overnight at 2-8 deg.C → adding serum albumin, uricase → mixing evenly → overnight at 2-8 deg.C → detecting and subpackaging.
The determination method comprises the following steps:
placing the reagent R1 and the reagent R2 prepared in examples 1-4 at the corresponding reagent position of a full-automatic blood coagulation analyzer (Hitachi 7180), sucking the reagent R1210 μ l, the reagent R270 μ l, the calibration solution or the specimen 10 μ l, the calibration solution concentration 300 μ M, the main/auxiliary wavelength 540/660nm, the two-point end point method, the reaction direction: and INC, calibrating and measuring creatinine values of various samples containing calcium dobesilate or etamsylate with different concentrations by using the calibration solution.
TABLE 3 measurement results of example 1: (unit: mu mol/L)
Measurement of | 1 | 2 | 3 | Mean value of | Relative deviation of |
Mother liquor | 356 | 355 | 356 | 355.7 | |
Calcium dobesilate 8ml/L | 357 | 355 | 356 | 356 | 0.1% |
Calcium dobesilate 16ml/L | 357 | 358 | 356 | 357 | 0.4% |
32ml/L calcium dobesilate | 356 | 356 | 355 | 355.7 | 0.0% |
Calcium dobesilate 64ml/L | 349 | 348 | 349 | 348.7 | 2.0% |
Etamsylate 12.5mg/L | 357 | 358 | 358 | 357.7 | 0.6% |
Etamsylate 25mg/L | 357 | 357 | 357 | 357.0 | 0.4% |
Etamsylate 50mg/L | 357 | 356 | 355 | 356.0 | 0.1% |
Etamsylate 100mg/L | 358 | 357 | 358 | 357.7 | 0.6% |
TABLE 4 measurement results of example 2: (unit: mu mol/L)
TABLE 5 results of the measurements of example 3: (unit: mu mol/L)
Measurement of | 1 | 2 | 3 | Mean value of | Relative deviation of |
Mother liquor | 360 | 360 | 362 | 361.0 | |
Calcium dobesilate 8ml/L | 360 | 360 | 362 | 360.7 | -0.1% |
Calcium dobesilate 16ml/L | 361 | 361 | 361 | 361 | 0.0% |
32ml/L calcium dobesilate | 360 | 360 | 359 | 359.7 | -0.4% |
Calcium dobesilate 64ml/L | 359 | 359 | 360 | 359.3 | -0.2% |
Etamsylate 12.5mg/L | 360 | 360 | 360 | 360.0 | -0.3% |
Etamsylate 25mg/L | 360 | 361 | 359 | 360.0 | -0.3% |
Etamsylate 50mg/L | 358 | 360 | 359 | 359 | -0.6% |
Etamsylate 100mg/L | 359 | 359 | 358 | 358.7 | -0.6% |
TABLE 6 measurement results of example 4: (unit: mu mol/L)
Measurement of | 1 | 2 | 3 | Mean value of | Relative deviation of |
Mother liquor | 360 | 360 | 360 | 360.0 | |
Calcium dobesilate 8ml/L | 361 | 360 | 361 | 360.7 | 0.2% |
Calcium dobesilate 16ml/L | 360 | 361 | 358 | 359.7 | -0.1% |
32ml/L calcium dobesilate | 359 | 359 | 358 | 358.7 | -0.4% |
Calcium dobesilate 64ml/L | 358 | 357 | 357 | 357.3 | -0.8% |
Etamsylate 12.5mg/L | 361 | 360 | 361 | 360.7 | 0.2% |
Etamsylate 25mg/L | 361 | 360 | 359 | 360.0 | 0% |
Etamsylate 50mg/L | 359 | 359 | 360 | 359.3 | -0.2% |
Etamsylate 100mg/L | 359 | 357 | 359 | 358.3 | -0.5% |
The results of the above examples 1-4 show that the uric acid kit capable of eliminating interference of calcium dobesilate and etamsylate in serum of the present invention can effectively eliminate interference of calcium dobesilate and etamsylate in uric acid measurement by adding high oxidation-reduction potential oxidized ferrate, or poly-metavanadate, or vanadium pentoxide or vanadyl trichloride, and the kit has good stability, simple operation, and rapid detection reaction, and particularly, peroxidase and uricase are respectively prepared in reagents R1 and R2, which is different from the existing kit components in the market, can prolong the stability of the kit in a period of time, continuously eliminate negative interference of calcium dobesilate and etamsylate, and avoid misjudgment of doctors in clinical diagnosis, can accurately use drugs and treatments, and is suitable for full-automatic biochemical analyzers.
Claims (7)
1. The utility model provides a quick uric acid kit of simply eliminating interference of calcium dobesilate, phenol sulfoethamine medicine in serum which characterized in that: the reagent comprises a reagent R1 and a reagent R2, wherein the reagent R1 comprises a buffer solution, peroxidase, ascorbic acid oxidase, a preservative, Trinder's reactant A, an oxidant and a nonionic surfactant; the reagent R2 comprises buffer, serum albumin, uricase, preservative, Trinder's reagent B and non-ionic surfactant; the Trinder's reactant A is 4-aminoantipyrine, the oxidant comprises any one of vanadium pentoxide, sodium ferrate, sodium metavanadate and vanadium oxychloride, and the Trinder's reactant B is one or a mixture of more than two of TOOS, DHBS, HDAOS, TBHBA, TOPS, TODB and 4-chlorophenol; in the R1, the concentration of a buffer solution is 5-200 mM, and the pH value is 6.5-9.5; the content of the peroxidase is 1.5-9 ku/liter; 1-10 ku/L ascorbic acid oxidase; trinder's reagent A0.3-5 mM/L; 0.01-0.5% of preservative by weight, and 0.1-10 mM of oxidant is adopted; the preservative is one or two of Proclin, gentamicin sulfate, PARABEN, chloramphenicol, sodium azide and borax.
2. The uric acid kit for rapidly and simply eliminating interference of calcium dobesilate and etamsylate medicines in serum according to claim 1, characterized in that: the peroxidase is bound to uricase.
3. The uric acid kit for rapidly and simply eliminating interference of calcium dobesilate and etamsylate medicines in serum according to claim 1, characterized in that: the buffer solution of the R1 is one or more of BES, BICINE, DIPSO, EPPS, PIPES, HEPES, MOPS, TAPS, TAPSO, TES, Tricine, Tris, glycylglycine and phosphate; the buffer solution of the reagent R2 is one or more of BES, BICINE, DIPSO, EPPS, PIPES, HEPES, MOPS, TAPS, TAPSO, TES, TRICINE, TRTS, glycylglycine and phosphate.
4. The uric acid kit for rapidly and simply eliminating interference of calcium dobesilate and etamsylate medicines in serum according to claim 1, characterized in that: the reagent R1 and the reagent R2 further contain nonionic surfactants, the weight ratio of the nonionic surfactants is 0.01-0.3%, and the nonionic surfactants are specifically one or two of BRIJ, EMULGEN, TRITON and TWEEN.
5. The uric acid kit for rapidly and simply eliminating interference of calcium dobesilate and etamsylate medicines in serum according to claim 1, characterized in that: the preservative is one or two of Proclin, gentamicin sulfate, PARABEN, chloramphenicol, sodium azide and borax.
6. The uric acid kit for rapidly and simply eliminating interference of calcium dobesilate and etamsylate medicines in serum according to claim 1, characterized in that: in the R2, the concentration of a buffer solution is 20-200 mM, and the pH value is 6.5-9.5; the uricase content is 5-20 ku/liter; the Trinder's reagent B content is 0.1-20 mM.
7. A preparation method of a uric acid kit for quickly and simply eliminating interference of calcium dobesilate and etamsylate medicines in serum is characterized by comprising the following steps:
preparation of R1 reagent:
weighing buffer solution → adding preservative → stirring and dissolving → adjusting PH to 8.0 with sodium hydroxide or hydrochloric acid → adding oxidant → stirring and dissolving → adjusting PH to 8.0 → adding Trinder's reactant A and nonionic surfactant, mixing evenly → 2-8 ℃ overnight → adding ascorbic acid oxidase and peroxidase → stirring and dissolving → 2-8 ℃ overnight → detecting, and subpackaging; the Trinder's reactant A is 4-aminoantipyrine, and the oxidant comprises any one of vanadium pentoxide, sodium ferrate, sodium metavanadate and vanadium oxychloride;
preparation of R2 reagent:
weighing buffer solution → adding preservative → stirring and dissolving → adjusting PH to 8.0 → adding Trinder's reactant B and surfactant → mixing evenly → overnight at 2-8 ℃ → adding serum albumin, uricase → mixing evenly → overnight at 2-8 ℃ → detecting and subpackaging, wherein the Trinder's reactant B is one or more than two of TOOS, DHBS, HDAOS, TBHBA, TOPS, TODB and 4-chlorophenol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011578743.9A CN112522364B (en) | 2020-08-15 | 2020-08-15 | Uric acid kit for rapidly and simply eliminating interference of calcium dobesilate and phenol sulfoethylamine drugs in serum |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010821509.8A CN111733211B (en) | 2020-08-15 | 2020-08-15 | Uric acid kit capable of eliminating interference of calcium dobesilate and etamsylate medicines in serum and preparation method thereof |
CN202011578743.9A CN112522364B (en) | 2020-08-15 | 2020-08-15 | Uric acid kit for rapidly and simply eliminating interference of calcium dobesilate and phenol sulfoethylamine drugs in serum |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010821509.8A Division CN111733211B (en) | 2020-08-15 | 2020-08-15 | Uric acid kit capable of eliminating interference of calcium dobesilate and etamsylate medicines in serum and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112522364A true CN112522364A (en) | 2021-03-19 |
CN112522364B CN112522364B (en) | 2023-09-08 |
Family
ID=72658520
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011578744.3A Active CN112522365B (en) | 2020-08-15 | 2020-08-15 | Preparation method of uric acid kit capable of eliminating interference of calcium dobesilate and phenol sulfoethylamine drugs in serum |
CN202011578745.8A Active CN112522366B (en) | 2020-08-15 | 2020-08-15 | Uric acid kit capable of eliminating interference of calcium dobesilate and phenol sulfoethylamine drugs in serum |
CN202011578366.9A Active CN112662736B (en) | 2020-08-15 | 2020-08-15 | Preparation method of uric acid kit for rapidly and simply eliminating interference of calcium dobesilate and phenol sulfoethylamine drugs in serum |
CN202011578743.9A Active CN112522364B (en) | 2020-08-15 | 2020-08-15 | Uric acid kit for rapidly and simply eliminating interference of calcium dobesilate and phenol sulfoethylamine drugs in serum |
CN202011578733.5A Pending CN112626170A (en) | 2020-08-15 | 2020-08-15 | Uric acid kit for quickly and simply eliminating drug interference and preparation method thereof |
CN202010821509.8A Active CN111733211B (en) | 2020-08-15 | 2020-08-15 | Uric acid kit capable of eliminating interference of calcium dobesilate and etamsylate medicines in serum and preparation method thereof |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011578744.3A Active CN112522365B (en) | 2020-08-15 | 2020-08-15 | Preparation method of uric acid kit capable of eliminating interference of calcium dobesilate and phenol sulfoethylamine drugs in serum |
CN202011578745.8A Active CN112522366B (en) | 2020-08-15 | 2020-08-15 | Uric acid kit capable of eliminating interference of calcium dobesilate and phenol sulfoethylamine drugs in serum |
CN202011578366.9A Active CN112662736B (en) | 2020-08-15 | 2020-08-15 | Preparation method of uric acid kit for rapidly and simply eliminating interference of calcium dobesilate and phenol sulfoethylamine drugs in serum |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011578733.5A Pending CN112626170A (en) | 2020-08-15 | 2020-08-15 | Uric acid kit for quickly and simply eliminating drug interference and preparation method thereof |
CN202010821509.8A Active CN111733211B (en) | 2020-08-15 | 2020-08-15 | Uric acid kit capable of eliminating interference of calcium dobesilate and etamsylate medicines in serum and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (6) | CN112522365B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112522365B (en) * | 2020-08-15 | 2023-12-26 | 中山标佳生物科技有限公司 | Preparation method of uric acid kit capable of eliminating interference of calcium dobesilate and phenol sulfoethylamine drugs in serum |
CN112710609B (en) * | 2020-12-23 | 2022-03-04 | 中生北控生物科技股份有限公司 | Anti-chyle interference uric acid determination kit |
CN114441516A (en) * | 2021-12-20 | 2022-05-06 | 苏州百源基因技术有限公司 | Uric acid detection kit and preparation method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT8019672A0 (en) * | 1980-02-04 | 1980-02-04 | Elvi Spa | METHOD FOR THE ELIMINATION OF BILIRUBIN INTERFERENCE IN THE DOSAGE OF HYDROGEN PEROXIDE BY MEANS OF A MODIFIED TRINDER REACTION. |
CN1778947A (en) * | 2004-11-23 | 2006-05-31 | 苏州艾杰生物科技有限公司 | Creatinine content determination and creatinine diagnostic reagent kit |
CN103278468A (en) * | 2013-05-24 | 2013-09-04 | 宁波美康生物科技股份有限公司 | Creatinine detection reagent |
CN104198408A (en) * | 2014-08-14 | 2014-12-10 | 上海睿康生物科技有限公司 | Detection kit for determining content of creatinine in serum by enzymic method |
CN108535244A (en) * | 2018-04-10 | 2018-09-14 | 波音特生物科技(南京)有限公司 | Creatinine content detection reagent in a kind of human serum of anti-Calcium Dobesilate interfering effects of drug |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103571916B (en) * | 2013-11-22 | 2016-03-16 | 重庆医科大学 | A kind of double reagent method measures the formula of uric acid content test kit |
CN104198473B (en) * | 2014-08-14 | 2017-07-07 | 上海睿康生物科技有限公司 | A kind of uric acid detection kit of stabilization |
CN106124779B (en) * | 2016-06-15 | 2019-10-18 | 中国医学科学院北京协和医院 | It is a kind of for measuring the kit and method of creatinine |
EP3258273B8 (en) * | 2016-06-15 | 2020-06-17 | Peking Union Medical College Hospital, Chinese Academy of Medical Sciences | A kit and method for detecting creatinine |
CN106367472B (en) * | 2016-09-29 | 2019-01-15 | 迈克生物股份有限公司 | For measuring the kit and method of uric acid |
CN108287233B (en) * | 2017-12-21 | 2021-04-23 | 山东博科生物产业有限公司 | Enzyme-method uric acid detection reagent with strong anti-interference capability |
CN108627654B (en) * | 2018-06-25 | 2021-03-16 | 武汉瀚海新酶生物科技有限公司 | Composition for eliminating interference of calcium dobesilate medicine on creatinine enzymatic detection |
CN111394424B (en) * | 2020-03-11 | 2023-09-29 | 海丰生物科技(北京)有限公司 | Human serum creatinine content detection reagent and method for resisting calcium dobesilate interference |
CN112522365B (en) * | 2020-08-15 | 2023-12-26 | 中山标佳生物科技有限公司 | Preparation method of uric acid kit capable of eliminating interference of calcium dobesilate and phenol sulfoethylamine drugs in serum |
-
2020
- 2020-08-15 CN CN202011578744.3A patent/CN112522365B/en active Active
- 2020-08-15 CN CN202011578745.8A patent/CN112522366B/en active Active
- 2020-08-15 CN CN202011578366.9A patent/CN112662736B/en active Active
- 2020-08-15 CN CN202011578743.9A patent/CN112522364B/en active Active
- 2020-08-15 CN CN202011578733.5A patent/CN112626170A/en active Pending
- 2020-08-15 CN CN202010821509.8A patent/CN111733211B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT8019672A0 (en) * | 1980-02-04 | 1980-02-04 | Elvi Spa | METHOD FOR THE ELIMINATION OF BILIRUBIN INTERFERENCE IN THE DOSAGE OF HYDROGEN PEROXIDE BY MEANS OF A MODIFIED TRINDER REACTION. |
CN1778947A (en) * | 2004-11-23 | 2006-05-31 | 苏州艾杰生物科技有限公司 | Creatinine content determination and creatinine diagnostic reagent kit |
CN103278468A (en) * | 2013-05-24 | 2013-09-04 | 宁波美康生物科技股份有限公司 | Creatinine detection reagent |
CN104198408A (en) * | 2014-08-14 | 2014-12-10 | 上海睿康生物科技有限公司 | Detection kit for determining content of creatinine in serum by enzymic method |
CN108535244A (en) * | 2018-04-10 | 2018-09-14 | 波音特生物科技(南京)有限公司 | Creatinine content detection reagent in a kind of human serum of anti-Calcium Dobesilate interfering effects of drug |
Non-Patent Citations (1)
Title |
---|
栗艳芳;茹利强;孔路科;连云芝;: "改良肌酐酶法试剂抗酚磺乙胺干扰能力的验证与评价", 实用医技杂志, no. 04 * |
Also Published As
Publication number | Publication date |
---|---|
CN112626170A (en) | 2021-04-09 |
CN112522365B (en) | 2023-12-26 |
CN112662736B (en) | 2024-02-02 |
CN111733211A (en) | 2020-10-02 |
CN112522366B (en) | 2024-06-04 |
CN112522366A (en) | 2021-03-19 |
CN112522365A (en) | 2021-03-19 |
CN112522364B (en) | 2023-09-08 |
CN112662736A (en) | 2021-04-16 |
CN111733211B (en) | 2021-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111733211B (en) | Uric acid kit capable of eliminating interference of calcium dobesilate and etamsylate medicines in serum and preparation method thereof | |
CN111733208B (en) | Creatinine kit capable of eliminating calcium dobesilate and etamsylate and preparation method thereof | |
CN104198473B (en) | A kind of uric acid detection kit of stabilization | |
CN111394424B (en) | Human serum creatinine content detection reagent and method for resisting calcium dobesilate interference | |
CA2722444C (en) | Acetaminophen assay | |
CN112029817B (en) | Creatinine detection kit and application method thereof | |
CN101942498B (en) | Kit for rapidly detecting diabetes | |
JP7465257B2 (en) | Acetaminophen Assay | |
JPS6091998A (en) | Novel enzymatic measurement of d-3-hydroxybutyric acid and acetoacetic acid in humors, urine and measurement reagent for it | |
CN113655006B (en) | Urinary system knot Dan Chengdan risk factor detection and test system | |
CN109541238A (en) | Direct bilirubin detecting method and kit | |
CN108107199A (en) | A kind of luminol chemiluminescence analysis measures the detection kit of uric acid | |
CN114441516A (en) | Uric acid detection kit and preparation method thereof | |
US20230384328A1 (en) | Creatinine Assay Kit with Desirable Stability and Capable of Rapidly Eliminating Drug Interference | |
CN112029820B (en) | Creatinine content detection kit for resisting calcium dobesilate interference and application thereof | |
JP3159273B2 (en) | Sorbitol measurement method and composition thereof | |
JP5808616B2 (en) | How to suppress the effects of interfering substances | |
CN114544606A (en) | Composition and kit for detecting content of lactic acid | |
JP2024017996A (en) | Reagent kit and quantification method for quantifying substance to be tested in sample | |
JPH02200200A (en) | Determining method of nadh and determination of bile acid using the same method | |
JPH0362400B2 (en) | ||
UV-LQ | Reactivos GPL | |
JPH03133397A (en) | Determination of creatinine and creatine and reagent composition therefor | |
JPS62104596A (en) | Activity measurement of guanase in humor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Rapid and Simple Uric Acid Kit for Eliminating the Interference of Calcium Hydroxybenzenesulfonate and Ethylphenidate Drugs in Serum Effective date of registration: 20231208 Granted publication date: 20230908 Pledgee: Zhongshan Torch High-tech Industrial Development Zone Branch of Agricultural Bank of China Co.,Ltd. Pledgor: Zhongshan BGH Biotechnology Co.,Ltd. Registration number: Y2023980070122 |